{‘She lacks zero experience’: the US healthcare establishment prepares for Høeg's role at the FDA.

As the United States continues making unprecedented adjustments to its vaccination recommendations, one figure appears in a surprising turn: Høeg, a US-based sports physician and epidemiologist who first made her name by casting doubt on Covid vaccines in the global health crisis and has zeroed in on possible fatalities after COVID-19 immunization in her short tenure at the US Food and Drug Administration (FDA).

Planned Shifts to Childhood Immunization Program

Health officials had intended to reveal sweeping changes to the pediatric immunization program recently, synchronizing the US with Denmark’s vaccine program, sources say – a substantial departure that would place the US at odds with many the world with no evidence for improved outcomes. The planned update has been pushed back until the new year.

Instead of Vinay Prasad, Høeg is set to present at the meeting. She was recently named interim head of the FDA’s drug evaluation center, the fifth appointee to run the center this calendar year.

Consolidating Power at the Agency

Høeg's temporary position might represent a closer partnership between the drug and biologics centers as Dr. Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it suggests a greater focus upon reevaluating previously authorized immunizations at the FDA.

Høeg has frequently advocated for discontinuing certain childhood vaccine recommendations in the US to become more like Denmark's approach, a nation with comprehensive healthcare and a number of inhabitants about the size of Wisconsin’s.

In her initial statements, she has persisted in emphasizing on immunizations – typically the purview of Dr. Prasad, director of the FDA’s vaccine center – instead of drug regulation.

Questions Over Background

Høeg has no apparent experience in medication creation, regulation or leadership, which has been standard for previous leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the agency head and CBER since earlier this year.

“She doesn’t seem to have the necessary background” for leading the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She lacks experience in leading a major agency. She has no expertise in industry regulation.”

Former directors of the center would “grasp regulatory frameworks and the research of drug development”, commented a former acting FDA commissioner. “Frankly, she has not acquired the type of experience that previous people who led CBER have had.”

The drug center has an enormous workload at the FDA, Woodcock emphasized.

“Everybody just focuses on the novel medication approvals, but the generic program authorizes numerous generic drugs. There is also a biosimilars division, over-the-counter program and other areas, and every single one must be managed,” she noted. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

Additionally, a significant leadership aspect to the job, which oversees in excess of 5,000 personnel. “It is a enormous leadership role, if you execute it properly,” the former official concluded.

Response and Contentious Policies

In response to inquiries about Dr. Høeg's credentials and whether this assignment indicates more teamwork among regulatory chiefs on immunizations, a spokesperson responded that the “concerns rely on incorrect presumptions”.

“Her experience is consistent with the responsibilities of her position,” the official stated, citing the months Dr. Høeg spent guiding the FDA commissioner on “medication safety and approval science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Dr. Høeg takes over the commissioner’s recently launched expedited review system, a disputed one-day drug-approval program that allegedly troubled her former heads. “How are these therapies being selected for this expedited pathway? Who makes the calls?” Dr. Howard said. “There is a lot of confidentiality occurring at the FDA right now.”

Broadly speaking, he remarked, “the FDA looks to be trending towards more relaxed oversight of all drugs, aside from vaccines.”

Public Track Record on Vaccines

Concerning immunizations, Dr. Høeg has a clearer, if concerning, track record, Howard have noted. She released a analysis using unverified volunteer-provided data to determine the rate of myocarditis following Covid vaccination. She consulted for the state of Florida top health official Dr. Joseph Ladapo, who allegedly have changed statistics to imply Covid vaccinations are pose a greater threat than they are.

Among her “policy goals” for the new government featured changing rules for new vaccines and discontinuing “optional” immunizations, she stated following the vote on a audio program. At the FDA, Høeg has according to sources proposed excluding teenage boys from receiving COVID-19 vaccinations.

“She’s an complete dogmatist who begins with her beliefs and reverse-engineers to retrofit the data in a highly deceptive, dishonest manner,” Howard said.

Gaining Influence and a “Campaign of Retribution”

Høeg joined fellow contrarians, {like|